[D1-A1]Opening Remarks
Wed. Mar 4, 2026 1:00 PM - 1:20 PM JST
Wed. Mar 4, 2026 4:00 AM - 4:20 AM UTC
Wed. Mar 4, 2026 4:00 AM - 4:20 AM UTC
Medium Hall(2nd Floor)
Sessions(by Program Type)
Symposium
[D1-A2]Advances and Challenges in Bioanalysis of Oligonucleotide Therapeutics
Wed. Mar 4, 2026 1:25 PM - 2:40 PM JST
Wed. Mar 4, 2026 4:25 AM - 5:40 AM UTC
Wed. Mar 4, 2026 4:25 AM - 5:40 AM UTC
Medium Hall(2nd Floor)
Chairman:Makoto Takahashi(Daiichi Sankyo Co., Ltd.), Miyuki Ugajin(Takeda Pharmaceutical Co., Ltd.)
[D1-A3]Challenge for Junior bioanalysts
Wed. Mar 4, 2026 4:10 PM - 5:40 PM JST
Wed. Mar 4, 2026 7:10 AM - 8:40 AM UTC
Wed. Mar 4, 2026 7:10 AM - 8:40 AM UTC
Medium Hall(2nd Floor)
Chairman:Hitoshi Uchiyama(Towa Pharmaceutical Co., Ltd.), Tamiki Mori(Mediford Corporation)
[D1-A4]Strategic activities of EBF towards the Future of Bioanalysis
Wed. Mar 4, 2026 5:50 PM - 6:40 PM JST
Wed. Mar 4, 2026 8:50 AM - 9:40 AM UTC
Wed. Mar 4, 2026 8:50 AM - 9:40 AM UTC
Medium Hall(2nd Floor)
Chairman:Takashi Miyayama(Chugai Pharmaceutical Co., Ltd.), Makoto Takahashi(Daiichi Sankyo Co., Ltd.)
[D2-A1]AI and Automation in Bioanalysis: Current Challenges and Future Directions
Thu. Mar 5, 2026 9:00 AM - 10:15 AM JST
Thu. Mar 5, 2026 12:00 AM - 1:15 AM UTC
Thu. Mar 5, 2026 12:00 AM - 1:15 AM UTC
Medium Hall(2nd Floor)
Chairman:Naohito Yamada(Shionogi & Co., Ltd.), Masayo Hashimoto(Otsuka Pharmaceutical Co., Ltd)
[D2-A2]Shaping the Future of Biomarker Evaluation: Insights from Practice
Thu. Mar 5, 2026 10:25 AM - 11:55 AM JST
Thu. Mar 5, 2026 1:25 AM - 2:55 AM UTC
Thu. Mar 5, 2026 1:25 AM - 2:55 AM UTC
Medium Hall(2nd Floor)
Chairman:Tomohiro Nishimoto(Nippon Shinyaku Co., Ltd.), Tomoko Arakawa(Pfizer R&D Japan G.K.)
[D2-A3]Issues and Solutions for Data Integrity in GLP: Exploring Best Practices through Discussions with PMDA, JSQA, and Bioanalysis Facilities
Thu. Mar 5, 2026 2:45 PM - 4:10 PM JST
Thu. Mar 5, 2026 5:45 AM - 7:10 AM UTC
Thu. Mar 5, 2026 5:45 AM - 7:10 AM UTC
Medium Hall(2nd Floor)
Chairman:Nozomu Koseki(Sunplanet Co.,Ltd.), Takeshi Okuzono(Sekisui Medical Co., Ltd.)
[D2-B1]Advancing Immunogenicity Assessment: The Latest Topics in ADA/NAb Assays and the Reporting Standardization
Thu. Mar 5, 2026 9:00 AM - 10:40 AM JST
Thu. Mar 5, 2026 12:00 AM - 1:40 AM UTC
Thu. Mar 5, 2026 12:00 AM - 1:40 AM UTC
Conference Room 408/409(4th Floor)
Chairman:Hisanori Hara(B2S Life Sciences), Hiroyuki Shimizu(Tanabe Pharma Corporation)
[D2-B2]Patent in Bioanalysis
Thu. Mar 5, 2026 2:45 PM - 4:10 PM JST
Thu. Mar 5, 2026 5:45 AM - 7:10 AM UTC
Thu. Mar 5, 2026 5:45 AM - 7:10 AM UTC
Conference Room 408/409(4th Floor)
Chairman:Makoto Takahashi(Daiichi Sankyo Co., Ltd.), Hisanori Hara(B2S Life Sciences)
[D3-A1]Moving Forward with ICH M10 Implementation: Challenges and Solutions
Fri. Mar 6, 2026 9:00 AM - 10:50 AM JST
Fri. Mar 6, 2026 12:00 AM - 1:50 AM UTC
Fri. Mar 6, 2026 12:00 AM - 1:50 AM UTC
Medium Hall(2nd Floor)
Chairman:Masayo Hashimoto(Otsuka Pharmaceutical Co., Ltd), Tomohiro Nishimoto(Nippon Shinyaku Co., Ltd.)
[D3-A2]Latest Approaches to Quantification and Biodistribution Evaluation of Gene Therapy Products
Fri. Mar 6, 2026 1:35 PM - 2:50 PM JST
Fri. Mar 6, 2026 4:35 AM - 5:50 AM UTC
Fri. Mar 6, 2026 4:35 AM - 5:50 AM UTC
Medium Hall(2nd Floor)
Chairman:Ken-ichi Yamamoto(Shin Nippon Biomedical Laboratories, Ltd.), Tamiki Mori(Mediford Corporation)
[D3-A3]Bioanalytical Strategy in Biopharmaceutical Development
Fri. Mar 6, 2026 3:05 PM - 3:55 PM JST
Fri. Mar 6, 2026 6:05 AM - 6:55 AM UTC
Fri. Mar 6, 2026 6:05 AM - 6:55 AM UTC
Medium Hall(2nd Floor)
Chairman:Masanori Nagata(Astellas Pharma Inc.), Takashi Miyayama(Chugai Pharmaceutical Co., Ltd.)
[D3-A4]Closing Remarks
Fri. Mar 6, 2026 4:00 PM - 4:25 PM JST
Fri. Mar 6, 2026 7:00 AM - 7:25 AM UTC
Fri. Mar 6, 2026 7:00 AM - 7:25 AM UTC
Medium Hall(2nd Floor)
13 results ( 1 - 13 )
- 1